MissionIR's  Instablog

Send Message
We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices. It is our unwavering commitment to connect the investment community with companies that have great potential and a strong dedication to... More
My company:
My blog:
MissionIR Blog
  • Boston Therapeutics, Inc. (BTHE) Takes Firm Stance Against Type 2 Diabetes, Backed By High-Potential Candidate Pipeline 0 comments
    Dec 9, 2013 2:03 PM | about stocks: BTHE

    Boston Therapeutics is developing a pipeline of therapeutic molecules based on complex carbohydrate chemistry. This pipeline currently carries three compounds that are being fine-tuned and tested in hopes that each will become a commercialized therapeutic treatment for diabetes.

    Drug candidate PAZ320 is being developed for the prevention of diabetes and related complications. PAZ320 is a non-systemic, non-toxic, chewable drug candidate that inhibits the enzymes that release glucose from complex carbohydrates in foods during digestion. By blocking this release, the drug reduces the amount of available glucose absorbed through the intestine.

    The company recently began enrollment for phase IIb trial in France to assess the efficacy and safety of PAZ320 in combination with metformin in patients with Type 2 diabetes. The company has also began preparation for an application of an investigational new drug (NYSE:IND) submission to the U.S. FDA for phase III trial in the U.S., Europe, Hong Kong, and China to evaluate the effects of PAZ320 on post-meal glucose levels in patients with Type 2 diabetes.

    In pre-clinical development is IPOXYN™, the company's injectable therapeutic agent that utilizes proprietary processes and patented technology to prevent necrosis, the death of tissue from inadequate blood flow, and treatment of ischemic conditions that may result in necrosis. Necrosis is the outcome of severe and acute injury such as from pathological conditions such as heart attack, brain injuries and stroke, as well as neurodegenerative diseases such as Alzheimer's disease, pancreatitis and many others. IPOXYN is targeting both human and animal tissues and organ systems deprived of oxygen and in need of metabolic support.

    Aside from a gap in diabetes treatments in humans, Boston Therapeutics also recognizes the unmet need in the veterinary market for blood replacement and oxygen delivery due to damage or ischemic tissue as a result of trauma, surgery anemia or other disease conditions. For this application the company is developing OXYFEX™, which can serve as the only available oxygen delivery mechanism for animals suffering ischemia or traumatic and surgical blood loss events. OXYFEX is also in pre-clinical development.

    Boston Therapeutics continues to advance its compounds to address the estimated 22 million people in the United States currently suffer from, and are enrolled in treatment for, Type 2 diabetes.

    For more information, visit bostonti.com

    MissionIR provides investor relations services to publicly traded companies in exchange for compensation. This article may be part of our efforts to widen a client's exposure. To read our full disclaimer, visit http://disclaimer.missionir.com

    Stocks: BTHE
Back To MissionIR's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers


More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.